Routine Laboratory Tests in Hospitalized PatientsThe Registered Nurse's Role
Professional organizations recommend against routinely obtaining common laboratory tests in hospitalized patients because such testing can result in harm associated with false positives, additional testing, overdiagnosis, and overtreatment. 1 The survey of inpatient providers at Memorial Sloan Kettering Cancer Center by Roman et al 2 suggests that routine laboratory testing remains common despite these recommendations. What we found most interesting about this article is that registered nurses were much more likely than other health care providers to value routine testing. Eighty percent of registered nurses believed that hospitalized patients should have daily laboratory testing, compared with 28% of attending physicians. Registered nurses do not generally order laboratory tests, but they are very important members of the inpatient hospital team, and their attitudes may influence ordering. In 2014, the American Academy of Nursing joined the American Board of Internal Medicine's Choosing Wisely campaign. The list of activities to avoid included several related to hospitalized adults: not letting older hospitalized patients lay in bed or only get up to move to a chair, not using physical restraints for older hospitalized patients, not waking patients for routine care, and not placing or maintaining a urinary catheter without a specific indication. 3 These are all evidence-based approaches to improve patient care, reduce harm, and reduce the cost of care. Perhaps the American Academy of Nursing should extend this list to not ordering routine laboratory tests in hospitalized patients as well. We categorized the postmarket studies by application type, regulatory authority, study type, and drug class. We further categorized interventional clinical trials by clinical focus; outcomes for trials with a primary efficacy end point were characterized as favorable or unfavorable. We used public data sources to identify sponsor size and ownership. With descriptive statistics, we examined study, drug and sponsor characteristics, and the publication frequency of study results at either the ClinicalTrials.gov website or in the scientific literature. Using logistic regression, we evaluated associations between publication rates for interventional clinical trials and study characteristics. The FDA Research Involving Human Subjects Committee waived approval because this was not considered human subjects research.
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Results | As of July 2016, 183 of the 288 postmarket studies (63.5%) meeting inclusion criteria were published in either the scientific literature or on the ClinicalTrials.gov website ( Table 1) ; more studies were published in journals (175 [60.8%]) than in the trial registry (87 [30.2%]). Interventional clinical trials (n=183) had a higher overall publication rate (87.4%) than all other study types combined (n=105 [21.9%]) (Fisher exact test; P < .001). Sponsors of interventional clinical trials were predominantly industry-affiliated, large, and publicly traded. Of 69 interventional clinical trials focused on efficacy, 82.6% were classified as having results favorable to the sponsor; studies with positive results (n = 57) were no more likely to be published than those with negative results (n = 12) (Fisher exact test; P = .17).
In multivariate analysis ( Table 2) , publication of interventional clinical trials on the ClinicalTrials.gov website was positively associated with safety and efficacy end points (odds ratio [OR], 9.68; 95% CI, 2.04-46.03), and original drug applications (OR, 2.70; 95% CI, 1.20-6.16); approval under Accelerated Approval (OR, 0.12; 95% CI, 0.03-0.50) was negatively associated. Although no significant predictors were found for publication in the scientific literature, all drug postmarket studies with nonindustry sponsors (n = 6) and those authorized under Accelerated Approval (n = 33) were published in journals. used to identify publications included the drug name, the patient population when known, and the target clinical condition specified in the PMR.
Discussion | In keeping with previous findings, our analysis demonstrates that postmarket study results are not consistently disseminated, either through journal publication or trial registries. The overall publication rate found here (63.5%) is lower than a previous finding that 86% of pivotal clinical trials supporting drug approvals are published, 4 but higher than the 51% publication rate reported for all postmarket device studies. 5 Limitations of our study included the relatively small sample size and lack of sponsor heterogeneity, which reduced our ability to identify factors predictive of publication. Although additional studies may still be intended for publication, this is unlikely because we allowed a minimum of 30 months between the date of study fulfillment and the assessment of publication. Despite calls for data sharing and publication of all clinical trial results, 2 publication rates for completed postmarket studies required by FDA remain relatively low. Although FDA publication of required postmarket studies would improve accessibility, this approach would likely require new regulations. Alternatively, increased sponsor commitment to submitting to journals, and to publishing all clinical trial results on trial registries, regardless of whether publication is legally required, may serve to promote dissemination of scientific knowledge. 
